TRHC’s new pharmacotherapy R&D institute to be based in Orlando
By Akshay Kedari  Date: 2019-02-23

TRHC’s new pharmacotherapy R&D institute to be based in Orlando

The newly established research institute will look forward to forging partnerships with significant pharmaceutical and academic entities in the region.

Tabula Rasa HealthCare, Inc., the renowned healthcare technology firm, has made it to the headlines for having declared the launch of its new Scientific Precision Pharmacotherapy Research and Development Institute. Reportedly, the Institute will be based out of Orlando, within Lake Nona Medical City.

According to sources familiar with the knowledge of the matter, TRHC's Research & Development Institute is strongly dedicated to developing proprietary products. These products apparently, will be aimed toward the optimization of medication regimes in order to reduce medical care expenditure, enhance patient outcomes, lower the healthcare service utilization, and manage risk. The Institute will also ensure the validation and recognition of these products from the scientific and regulatory communities.

Reportedly, the research vision of the TRHC Institute expands with the new research initiatives cropping up, inclusive of biomedical engineering systems, translational research, patient-specific information, nanoscale science, data-driven technologies and solutions, and bioinformatics.

According to an official press release by Tabula Rasa HealthCare, Calvin H. Knowlton, the CEO & Chairman of the company, stated that the new research institute intends to focus on enhancing the firm’s decision support tools via extensive research, deploying computer simulations, computational modeling, and pharmacokinetics & pharmacodynamics modeling. The basic objective here is to optimize and manufacture novel products in association with the company’s Medication Risk StratificationTM and Medication Risk MitigationTM technologies, Knowlton claimed.

Dr. Jacques Turgeon, Chief Scientific Officer, TRHC, stated that the institute will aim to forge partnerships with academic and pharmaceutical entities, and also look forward to the opportunity to join hands with globally acclaimed organizations.

Commenting further on the launch, Knowlton affirmed that the company is thrilled to not only be a part of the innovation prevalent in Lake Nona Medical City, but also to have gained the guidance of Dr. Michaud and Dr. Turgeon, stalwarts recognized for their expertise in pharmacokinetics & drug-metabolism and research and pharmacy education respectively.

Dr. Jacques Turgeon, BPharm, PhD, for the record, has been named the CEO of the TRHC Institute, while Dr. Veronique Michaud, BPharm, PhD, will be filling in the place of the institute’s Chief Operating Officer.

About Author

Akshay Kedari    

Akshay Kedari

A qualified computer engineering graduate, Akshay Kedari takes pride in having his way with words. Following his passion for content creation, he writes insightful pieces on aeresearch.net and a few other portals. Also endorsed with a short-term experience in web deve...

Read More

More News By Akshay Kedari

Fibonacci Brands acquires Darwin from Harvest Health & Recreation
Fibonacci Brands acquires Darwin from Harvest Health & Recreation
By Akshay Kedari

Fibonacci Brands has recently announced the acquisition of Darwin from Harvest Health & Recreation (HARV.CN) as its foundation brand. Fibonacci is a leading player in the international cannabis industry. According to James George, founder of Fib...

GVN adds EVIT Center and Chumakov as its new Centers of Excellence
GVN adds EVIT Center and Chumakov as its new Centers of Excellence
By Akshay Kedari

The Global Virus Network (GVN), an international coalition of medical virologists, has recently announced the addition of Australian and Russian researchers. GVN is adding the Center for EVIT (Emerging Viruses, Inflammation & Therapeutics) of th...

Wind Point Partners takes over RTIC to expand business portfolio
Wind Point Partners takes over RTIC to expand business portfolio
By Akshay Kedari

American private equity firm, Wind Point Partners has recently signed an acquisition deal with the one of the biggest direct-to-consumer (D2C) eCommerce providers of drinkware, RTIC. Reportedly, RTIC is Wind Point’s third acquisition of a famil...

Novartis reveals positive data from Phase III ORION trials of inclisiran
Novartis reveals positive data from Phase III ORION trials of inclisiran
By Akshay Kedari

Swiss multinational pharmaceutical firm, Novartis has recently announced results from its Phase III ORION-10 and -11 studies that focus on assessing the individual responses of patients on lowering low-density lipoprotein cholesterol (LDL-C) with inc...

Medtronic to acquire Companion Medical to expand diabetes business
Medtronic to acquire Companion Medical to expand diabetes business
By Akshay Kedari

Medtronic plc, the global leader in medical technologies, has reportedly announced that it is planning to acquire insulin pen manufacturer Companion Medical. The acquisition gives Medtronic access to Companion Medical’s ‘InPen’, wh...